We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Cause of Warburg Micro Syndrome Identified

By LabMedica International staff writers
Posted on 25 Nov 2013
A gene responsible for Warburg Micro syndrome, a rare genetic disease characterized by eye, brain, and endocrine abnormalities, has been identified by mutation screening.

Patients with Warburg Micro syndrome are severely challenged physically and mentally, unable to learn how to walk or speak, and become blind and paralyzed from an early age. More...


A collaborative team of scientists led by those at the Medical College of Wisconsin (Milwaukee, WI, USA) and the University of Edinburgh (UK) studied a cohort consisting of 77 individuals with a spectrum of Warburg micro syndrome (WARBM) disorders including 59 typical WARBM cases, five with the milder Martsolf syndrome, and 13 atypical cases. Some complementary studies were conducted in a murine model.

Mutation screening of the complete coding region of TBC1 Domain Family, Member 20 (TBC1D20), and three members of the RAS Oncogene Family RAB1A, RAB1B, and RAB2A was performed by direct sequence analysis in both directions by using genomic DNA extracted from venous blood. Real-time polymerase chain reaction (qPCR) analysis of genomic DNA from one individual was carried out on a LightCycler 480 (Roche Applied Science; Indianapolis, IN, USA) with primers designed to amplify coding regions of TBC1D20 as well as the 5′ and 3′ genes RanBP-Type and C3HC4-Type Zinc Finger Containing 1(RBCK1).

Clinical evaluation of individuals carrying pathogenic TBC1D20 mutations was sufficient to conclude that they cause a disease phenotype indistinguishable to that caused by mutations in genes encoding for Rab3 GTPase-activating protein catalytic subunit, RAB3GAP1, RAB3GAP2, or RAB18. The four genes do not comprise the full causative picture for Warburg Micro syndrome; in about half of the cases, the causing mutation was in none of those genes, which means there are additional novel genes contributing to the disease.

Duska J. Sidjanin, PhD, an associate professor of cell biology, neurobiology and anatomy and senior author of the study said, “These findings have implications not only for families affected with Warburg Micro syndrome, but also provide novel information about the genes and molecular pathways essential for human development that is relevant for more common developmental disorders such as epilepsy and autism.” The study was published on November 14, 2013, in the American Journal of Human Genetics.

Related Links:

Medical College of Wisconsin
University of Edinburgh 
Roche Applied Science



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.